Translational Program

Zenith is using a combination of high-throughput in silico assays, in vitro genetic and phenotypic screens, and in vivo model systems to identify suitable epigenetic targets and potential therapeutic applications.  By analyzing the specific biological pathways targeted by its inhibitors, predictive biomarkers of response and patient stratification approaches are elaborated and tested in the clinic through a robust translational medicine platform.  This strategy allows the design, characterization, and clinical development of novel epigenetic inhibitors that can be tailored to specific medical needs, and develop biomarkers to identify potential patients that could benefit from such therapies.